Teva Pharmaceuticals USA, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$81Mgeneral payments (2019-2025)
$3.5Mresearch payments (2019-2025)
100,455clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $13M
2020 $7.8M
2021 $9.6M
2022 $9.3M
2023 $12M
2024 $14M
2025 $15M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Psychiatry $31M
Neurology (Psychiatry & Neurology) $24M
Psychiatric/Mental Health (Nurse Practitioner) $7.9M
Family $2.0M
Family Medicine $1.6M
Physician Assistant $1.4M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Richard Jackson Boca Raton, FL Psychiatry $1,254,091.58
Cherian Karunapuzha Oklahoma City, OK Neurology (Psychiatry & Neurology) $1,097,766.07
Gustavo Alva Orange, CA Psychiatry $1,064,391.41
Fahd Amjad Washington, DC Neurology (Psychiatry & Neurology) $1,058,631.48
Rakesh Jain Lake Jackson, TX Psychiatry $983,697.18
Leslie Citrome Pomona, NY Psychiatry $967,665.97
Amber Hoberg Hillsboro, OR Psychiatric/Mental Health (Nurse Practitioner) $923,175.75
Arvinder Pal Walia Austin, TX Psychiatry $727,697.44
Craig Chepke Huntersville, NC Psychiatry $636,591.53
Andrew Cutler Lakewood Ranch, FL Psychiatry $631,014.07

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.